Payment overview · 2025
General Payments
$174.61
7 reported records · 5 companies
Healthcare provider profile · identity verified
William M Sheppard, MD
Allopathic & Osteopathic Physicians|Family Medicine · LUDINGTON, MI · NPI 1932142221
Verified facts
What the public records show
CMS Open Payments records show William M Sheppard, MD received $174.61 in general payments during 2025 across 7 reported records.
Globus Medical, Inc. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $46.63 | 26.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.70 | 25.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.97 | 18.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.27 | 15.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.04 | 13.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $174.61 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RELINE Normalized: reline |
Device | Globus Medical, Inc. | $46.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.70 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 508 | 127 |
| Lisinopril | Lisinopril | 408 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 73 |
| Losartan Potassium | Losartan Potassium | 273 | 66 |
| Omeprazole | Omeprazole | 260 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 245 | 67 |
| Gabapentin | Gabapentin | 227 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 53 |
| Potassium Chloride | Potassium Chloride | 193 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 53 |
| Metformin Hcl | Metformin Hcl | 187 | 40 |
| Simvastatin | Simvastatin | 169 | 34 |
| Furosemide | Furosemide | 157 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 30 |
| Prednisone | Prednisone | 132 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 45 |
| Trazodone Hcl | Trazodone Hcl | 119 | 31 |
| Meloxicam | Meloxicam | 118 | 25 |
| Sertraline Hcl | Sertraline Hcl | 109 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 23 |
| Eliquis | Apixaban | 106 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 20 |
| Metformin Hcl Er | Metformin Hcl | 83 | 19 |
| Famotidine | Famotidine | 82 | 17 |
| Montelukast Sodium | Montelukast Sodium | 71 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 13 |
| Glimepiride | Glimepiride | 69 | 14 |
| Allopurinol | Allopurinol | 65 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 17 |
| Buspirone Hcl | Buspirone Hcl | 63 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 12 |
| Pregabalin | Pregabalin | 59 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 24 |
| Atenolol | Atenolol | 49 | 14 |
| Celecoxib | Celecoxib | 49 | 14 |
| Cephalexin | Cephalexin | 46 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Jardiance | Empagliflozin | 46 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | suppressed |
| Carvedilol | Carvedilol | 44 | 12 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Bupropion Hcl | Bupropion Hcl | 43 | suppressed |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 23 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 12 |
| Tramadol Hcl | Tramadol Hcl | 34 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Indapamide | Indapamide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | 11 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Orencia Clickject | Abatacept | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174.61 · 7 records | Globus Medical, Inc. | AREXVY, CAPLYTA, KRYSTEXXA, Ozempic, RELINE, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error